Large Molecule

Bristol-Myers Squibb to Build Biologics Facility in Ireland

Nov 19, 2014

Bristol-Myers Squibb Company plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio.

Bristol-Myers Squibb's portfolio includes approved and investigational biologic medicines across multiple therapeutic areas including oncology, virology and immunoscience. Biologic medicines are an increasingly important tool in the treatment of serious diseases and comprise more than half of Bristol-Myers Squibb’s research and development pipeline.

“Our investment in this new facility reflects the strength of our business and the increasingly important role that biologic medicines will play in Bristol-Myers Squibb’s future,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “For 50 years, Bristol-Myers Squibb has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy through this significant expansion of our manufacturing capability.”

“I greatly welcome this investment by Bristol-Myers Squibb, which is a huge boost to the Irish economy,” said Mr. Enda Kenny T.D., Prime Minister of Ireland. “I had the opportunity to meet with Bristol-Myers Squibb, and I'm delighted they chose Ireland as the location for this large, state-of-the-art facility. Not only will 1,000 construction jobs be created in the initial phase, but the facility will support up to 400 jobs for skilled professionals...”

According to a press release, the 30,000-square meter project will house six 15,000-liter bioreactors and a purification area as well as office and laboratory space. The plant will be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant.

The full cost of the facility, expected to be finalized in the second half of 2015, is anticipated to be comparable to the approximately $900 million investment to construct and operationalize the company’s biologics manufacturing facility in Devens, Massachusetts.

Approximately 350 to 400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the facility when construction is completed, and the construction program is expected to create about 1,000 jobs. The completion of the facility, including commissioning and validation, is anticipated to take approximately four years and is estimated to be operational in 2019.